Comparison of Two New Generation Drug Eluting Stents in Patients With Diabetes (OCT-DES)

Inclusion criteria

• Known to have diabetes
• Scheduled for percutaneous coronary intervention (PCI) with a stenosis suitable for DES implantation and OCT imaging
• Reference vessel diameter over 2.5mm by operator assessment.
• Able to understand and sign the written Informed Consent Form.
• Able and willing to follow the Protocol requirements.

Exclusion criteria

• Inability to consent
• Cardiogenic shock
• Planned use of a bare metal stent
• LMS coronary artery disease
• Congestive cardiac failure or low ejection fraction (LVEF <35%)
• Lesions unsuitable for OCT
• Total length of stented lesion greater than 55mm (total combination of stent lengths)
• Age less than 18 years or age greater than 80 years
• Planned surgical procedure ≤ 12 months post PCI procedure
• Patient demonstrates evidence of thrombocytopenia (platelet count < 100,000/mm3)
• Patients with contraindications to ASA, clopidogrel, or prasogrel
• Patient is currently on warfarin, or possibility of treatment with warfarin during the following 12 months post index procedure
• Allergy to contrast
• Patients enrolled in another active clinical trial.
• Potential for non-compliance towards the requirements in the study protocol.
• Serious known concomitant disease with a life expectancy of less than one year
• Follow-up impossible (no fixed abode, etc)
• Patients with renal impairment (Creatinine >200mmol/L)
• Subjects of childbearing potential